ARS Pharmaceuticals, Inc. (SPRY)
| Market Cap | 412.71M -55.6% |
| Revenue (ttm) | 116.93M +4.1% |
| Net Income | -215.43M |
| EPS | -2.18 |
| Shares Out | 99.45M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,873,172 |
| Open | 4.260 |
| Previous Close | 4.165 |
| Day's Range | 4.120 - 4.300 |
| 52-Week Range | 4.120 - 13.150 |
| Beta | 1.00 |
| Analysts | Strong Buy |
| Price Target | 22.50 (+442.17%) |
| Earnings Date | Aug 13, 2026 |
About SPRY
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.
Financial Performance
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for SPRY stock is "Strong Buy." The 12-month stock price target is $22.5, which is an increase of 442.17% from the latest price.
News
Kaplan Fox Urges ARS Pharmaceuticals Inc. (SPRY) Investors Seeking Recovery to Contact the Firm Before October 5, 2026
New York, New York--(Newsfile Corp. - September 16, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against ARS Pharmaceuticals Inc. ("ARS" or the "Company") (...
ARS Pharmaceuticals Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
neffy continues to gain market share in a large, underserved allergy market, with a strategic focus on provider engagement and operational efficiency. The CSU program is advancing, leveraging existing infrastructure, with key interim data expected in Q1 next year. Cash position remains strong at $144 million.
Kaplan Fox Encourages ARS Pharmaceuticals Inc. (SPRY) Investors to Contact the Firm Before the Lead Plaintiff Deadline on October 5, 2026
New York, New York--(Newsfile Corp. - September 8, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against ARS Pharmaceuticals Inc. ("ARS" or the "Company") (N...
ARS Pharmaceuticals price target lowered to $15 from $18 at Leerink
Leerink lowered the firm’s price target on ARS Pharmaceuticals (SPRY) to $15 from $18 and keeps an Outperform rating on the shares.
ARS Pharmaceuticals to Participate in Upcoming Investor Conferences
SAN DIEGO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to treat and prevent s...
Kaplan Fox Notifies ARS Pharmaceuticals Inc. (SPRY) Investors of an Upcoming Lead Plaintiff Deadline on October 5, 2026
New York, New York--(Newsfile Corp. - August 31, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against ARS Pharmaceuticals Inc. ("ARS" or the "Company") (NAS...
SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of October 5, 2026 in ARS Pharmaceuticals Inc. Lawsuit - SPRY
Wall Street called the missed CVS Caremark formulary date a "negative shock" — a securities class action alleges ARS Pharmaceuticals built analyst expectations on a July 1, 2026 coverage timeline that...
SPRY Investors Have Rights – If You Lost Money Investing in ARS Pharmaceuticals Inc. Contact Robbins LLP for Information Recovering Your Losses
SAN DIEGO, Aug. 21, 2026 (GLOBE NEWSWIRE) -- Robbins LLP reminds shareholders that a securities class action has been filed on behalf of all investors who purchased or otherwise acquired ARS Pharmaceu...
Kaplan Fox Urges Investors of ARS Pharmaceuticals Inc. (SPRY) with Significant Losses to Seek a Leadership Role Before October 5, 2026
New York, New York--(Newsfile Corp. - August 17, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against ARS Pharmaceuticals Inc. ("ARS" or the "Company") (NAS...
ARS Pharmaceuticals reports Q2 EPS (63c), consensus (49c)
Reports Q2 revenue $33.66M, consensus $31.32M. “It is a privilege to lead ARS Pharma at this pivotal time, and my conviction in the opportunity ahead has only grown since stepping…
ARS Pharmaceuticals sees cash flow break-even by end of 2027
The company said in its earnings release, “Based on its revised cash-based expense plan, ARS Pharma anticipates a path to reaching cash flow breakeven by the end of 2027.” ARS…
ARS Pharmaceuticals names Meg Smith as Chief Commercial Officer
ARS Pharmaceuticals (SPRY) announced the appointment of Meg Smith as Chief Commercial Officer, effective August 17. Smith most recently led the commercial organization at Dynavax Technologies. “neffy ...
Kaplan Fox Reminds ARS Pharmaceuticals Inc. (SPRY) Investors Seeking Recovery of the Lead Plaintiff Deadline on October 5, 2026
New York, New York--(Newsfile Corp. - August 14, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against ARS Pharmaceuticals Inc. ("ARS" or the "Company") (NAS...
ARS Pharmaceuticals Earnings Call Transcript: Q2 2026
Q2 revenue reached $33.7M with neffy U.S. market share doubling year-over-year to 5%. Strategic focus shifted to provider engagement, cost discipline, and pipeline expansion, with cash flow breakeven targeted by end of 2027.
ARS Pharmaceuticals Earnings release: Q2 2026
ARS Pharmaceuticals released its Q2 2026 earnings on August 13, 2026, summarizing the period's financial results.
ARS Pharmaceuticals Quarterly report: Q2 2026
ARS Pharmaceuticals has published its Q2 2026 quarterly earnings report on August 13, 2026.
ARS Pharmaceuticals Outlines Strategic Priorities, including a Focused Commercial Strategy, and Reports Second Quarter 2026 Financial Results
$26.2 million in U.S. neffy ® net product revenue in Q2 2026; total U.S. epinephrine market share for Type 1 allergies of 5% and 8% share within field-targeted accounts
Grabar Law Office Investigates Claims on Behalf of Long-Term Shareholders of ARS Pharmaceuticals, Inc. (SPRY)
Philadelphia, Pennsylvania--(Newsfile Corp. - August 13, 2026) - Grabar Law Office is investigating claims on behalf of shareholders of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY). What is The Investigat...
ARS Pharmaceuticals Announces Conference Call and Webcast on August 13 Outlining its Updated Strategic Priorities and Reporting Second Quarter 2026 Financial Results
SAN DIEGO, Aug. 03, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patie...
ARS Pharmaceuticals announces CEO succession
The company states: “ARS Pharmaceuticals (SPRY) announced a CEO succession, in which co-founder and CEO Richard Lowenthal will no longer serve as an employee and officer of the company effective…
ARS Pharmaceuticals Announces CEO Succession
Richard Lowenthal, Chief Executive Officer, Transitioning following More than a Decade of Leadership Since Co-Founding the Company
ARS reports no new commercial formulary additions, coverage decisions for neffy
ARS Pharmaceuticals (SPRY) provided an update on payer access for neffy epinephrine nasal spray and an updated financial outlook for 2026 and 2027. Despite certain payer discussions ongoing until mid-...
ARS Pharmaceuticals Provides Commercial and Financial Updates
No new commercial formulary additions or coverage decisions issued for neffy (epinephrine nasal spray) in the July 1, 2026 cycle; company to continue payer discussions for potential future inclusion
ARS Pharmaceuticals price target raised to $30 from $12 at Cantor Fitzgerald
Cantor Fitzgerald raised the firm’s price target on ARS Pharmaceuticals (SPRY) to $30 from $12 and keeps an Overweight rating on the shares. Focus has centered on the company’s neffy…
ARS Pharmaceuticals Earnings Call Transcript: Q1 2026
Q1 2026 revenue reached $22.7M, driven by strong neffy adoption and expanded access. Key initiatives to reduce prescribing friction and improve affordability are expected to accelerate growth, with CVS Caremark approval and back-to-school season poised to boost demand.